Karyopharm
Newton, US · 3 known investors
Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
Founders & leadership
SP
Stuart PoultonExecutive
MM
Michael ManoExecutive
RR
Reshma RangwalaExecutive
RP
Richard PaulsonExecutive
SM
Stephen MitchenerExecutive
MM
Michael MasonExecutive
PH
Peter HonigNamed on SEC filing
CS
Chen SchorNamed on SEC filing
Board
DR
Deepika R. PakianathanBoard director
BE
Barry E. GreeneBoard director
MR
Mansoor Raza MirzaBoard director
GG
Garen G. BohlinBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$165M disclosed across 1 round · 2022
▶$165MraisedDec 2022 · 33 investors · PharmaceuticalsRule 506(b)
▶$165MraisedDec 2022 · 33 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Peter HonigDirector
- Barry E. GreeneDirector
- Stuart PoultonExecutive Officer
- Michael ManoExecutive Officer
- Reshma RangwalaExecutive Officer
- Richard PaulsonExecutive Officer, Director
- Deepika R. PakianathanDirector
- Chen SchorDirector
- Stephen MitchenerExecutive Officer
- Michael MasonExecutive Officer
- Mansoor Raza MirzaDirector
- Garen G. BohlinDirector
- Christy J. OligerDirector
- Sohanya ChengExecutive Officer
- Offering amount
- $165M
- Amount sold
- $165M
- Sales commissions
- $9.9M
- Placement agents
- Robert W. Baird & Co. Incorporated, Piper Sandler & Co., Jefferies LLC, Barclays Capital, Inc., H.C. Wainwright & Co. LLC
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Seeking Alpha37 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood36 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Kite Pharma35 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with Karyopharm for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Karyopharm do?
- Karyopharm is a pharmaceutical company developing drugs based on its SINE (Selective Inhibitor of Nuclear Export) technology, with medicines targeting cancers including multiple myeloma and diffuse large B-cell lymphoma. It serves patients and healthcare providers in oncology.
- Who are Karyopharm's investors?
- Karyopharm's investors include Avoro Capital Advisors, Foresite Capital, HEALTHCARE ROYALTY PARTNERS.
- How much funding has Karyopharm raised?
- Karyopharm has disclosed $165M raised across 1 round.
- Where is Karyopharm headquartered?
- Karyopharm is headquartered in Newton, US.